Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Atrial Fibrillation

Therapeutic area intelligence for Atrial Fibrillation with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Companies
2

Companies

Anthos Therapeutics →
Johnson & Johnson →

Assets

abelacimab →
CCTA →
Farapulse →
Johnson →
Medtronic →

Recent signals(9)

ClinicalJuly 29, 2026

Study on BDNF Levels and Atrial Cardiomyopathy in AF Ablation Patients

A clinical trial is assessing the correlation between circulating BDNF levels and atrial cardiomyopathy in patients undergoing ablation for persistent atrial fibrillation.

ClinicalJuly 29, 2026

Study on Myocardial Injury in Rapid Atrial Fibrillation Patients

This observational study aims to assess the relationship between troponin levels, myocardial injury, and coronary artery disease in rapid AF patients.

ClinicalJuly 28, 2026

CCTA May Enhance Risk Stratification for Atrial Fibrillation Ablation Outcomes

A study is evaluating the predictive value of CCTA parameters for post-ablation outcomes in atrial fibrillation patients.

ClinicalJuly 26, 2026

Registry Launched to Evaluate Farapulse PFA Technology for Atrial Fibrillation

The DISRUPT-AF Registry aims to gather real-world clinical data on the Farapulse Pulsed Field Ablation System for AF treatment.

ClinicalJuly 26, 2026

Johnson & Johnson's Varipulse Catheter Study Targets Paroxysmal Atrial Fibrillation

A clinical trial is underway to evaluate the long-term effectiveness of the Varipulse Catheter in patients with paroxysmal atrial fibrillation under optimized sedation.

ClinicalJuly 14, 2026

Anthos and Novartis initiate LILAC-TIMI 76 trial for abelacimab in high-risk AF patients

The LILAC-TIMI 76 study is evaluating abelacimab's efficacy and safety in high-risk atrial fibrillation patients unsuitable for oral anticoagulation.

ClinicalJuly 7, 2026

Study on Non-Invasive Median Nerve Stimulation for Atrial Fibrillation Post-Ablation

A clinical trial is assessing the efficacy of the CardiaCare RR2 wearable device for reducing atrial arrhythmias after AF ablation.

ClinicalJune 23, 2026

Study on Unipolar Voltage Mapping for Personalized Atrial Fibrillation Ablation Initiated

A clinical trial is underway to evaluate unipolar voltage mapping for personalized catheter ablation in atrial fibrillation patients.

ClinicalJune 17, 2026

Study on PSB Pacing to Prevent Atrial Fibrillation in Sinus Node Dysfunction Patients

A clinical trial is evaluating the effectiveness of posterosuperior bundle pacing in reducing atrial fibrillation incidence in patients with sinus node dysfunction.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.